7 news items
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
TAK
9 May 24
approvals from the U.S. FDA in FY2023, Takeda's performance demonstrates the potential of our pipeline and our ability to bring our innovative medicines
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
TAK
22 Apr 24
Japan and toward the creation of innovative therapeutics
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
TAK
27 Mar 24
gastrointestinal diseases is unwavering. Alongside our continuous work on innovative treatments within our gastroenterology portfolio, we recognize the significant
Takeda Announces Approval Of ADZYNMA Intravenous Injection 1500 In Japan For Patients With Congenital Thrombotic Thrombocytopenic Purpura
TAK
26 Mar 24
option specifically approved to treat this ultra-rare condition," said Yasushi Kajii, Head, R&D Japan Region at Takeda. "Developing innovative
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
TAK
26 Feb 24
esteemed history and global presence, we are honored to advance our vision of delivering highly innovative medicines and transformative care worldwide
p68plw0onpay4u1k0xt
TAK
26 Feb 24
and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier
hd4kpmgng5bn5 3pc4zjphiwy31326b4uss6l4o3vieq8md
TAK
13 Feb 24
investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference
- Prev
- 1
- Next